Abbott Laboratories $ABT Shares Sold by Moody National Bank Trust Division

Moody National Bank Trust Division reduced its stake in Abbott Laboratories (NYSE:ABT) by 26.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 15,278 shares of the healthcare product maker’s stock after selling 5,562 shares during the quarter. Moody National Bank Trust Division’s holdings in Abbott Laboratories were worth $1,914,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in ABT. Charles Schwab Trust Co raised its holdings in shares of Abbott Laboratories by 109.8% in the third quarter. Charles Schwab Trust Co now owns 29,412 shares of the healthcare product maker’s stock valued at $3,939,000 after buying an additional 15,394 shares during the last quarter. Danica Pension Livsforsikringsaktieselskab acquired a new position in Abbott Laboratories in the 3rd quarter valued at $185,640,000. Asset Management One Co. Ltd. raised its position in Abbott Laboratories by 2.4% during the 3rd quarter. Asset Management One Co. Ltd. now owns 858,834 shares of the healthcare product maker’s stock worth $115,032,000 after buying an additional 19,966 shares during the last quarter. Nordea Investment Management AB raised its stake in shares of Abbott Laboratories by 6.1% during the 3rd quarter. Nordea Investment Management AB now owns 329,430 shares of the healthcare product maker’s stock worth $43,785,000 after buying an additional 18,974 shares in the last quarter. Finally, AE Wealth Management LLC increased its holdings in shares of Abbott Laboratories by 20.8% in the 3rd quarter. AE Wealth Management LLC now owns 65,504 shares of the healthcare product maker’s stock valued at $8,774,000 after purchasing an additional 11,264 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Trading Down 0.7%

Shares of ABT opened at $104.10 on Wednesday. The business’s 50-day moving average price is $111.95 and its 200 day moving average price is $122.57. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $181.31 billion, a P/E ratio of 27.98, a P/E/G ratio of 1.67 and a beta of 0.74. Abbott Laboratories has a 1-year low of $102.41 and a 1-year high of $139.06.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting the consensus estimate of $1.50. The business had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period last year, the firm posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a $0.63 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.4%. Abbott Laboratories’s dividend payout ratio is presently 67.74%.

Analysts Set New Price Targets

ABT has been the topic of a number of analyst reports. Weiss Ratings cut Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 26th. Freedom Capital upgraded Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 29th. Daiwa Securities Group cut their target price on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a research report on Friday, January 30th. Sanford C. Bernstein cut their price target on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Finally, BTIG Research lowered their price objective on Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $136.16.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 885 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $102,288.30. Following the completion of the sale, the executive vice president directly owned 146,377 shares in the company, valued at $16,918,253.66. The trade was a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Daniel J. Starks purchased 10,000 shares of the business’s stock in a transaction dated Wednesday, February 4th. The shares were acquired at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the acquisition, the director directly owned 6,738,817 shares in the company, valued at $732,711,572.41. This represents a 0.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have sold a total of 3,055 shares of company stock valued at $353,097 in the last ninety days. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.